Need professional-grade analysis? Visit stockanalysis.com
$10.13B
56.58
1,807
N/A
Liaoning Chengda Biotechnology Co. Ltd. A (688739) trades on SHG in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY24.38, down 1.65% from the previous close.
Over the past year, 688739 has traded between a low of CNY23.89 and a high of CNY29.47. The stock has gained 2.0% over this period. It is currently 17.3% below its 52-week high.
Liaoning Chengda Biotechnology Co. Ltd. A has a market capitalization of $10.13B, with a price-to-earnings ratio of 56.58.
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company's rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant human papillomavirus 15-valent vaccine is in phase II; and 13-valent pneumococcal polysaccharide conjugate and varicella, as well as the live meningococcal A, C, Y and W-135 conjugate vaccine are in phase I. Its Serogroup B meningococcal outer membrane vesicle, 20-valent pneumococcal polysaccharide conjugate, recombinant zoster vaccine, multivalent HFMD (hand foot and mouth disease), high-dose influenza, and inactivated rabies monoclonal antibody vaccine are in the pre-clinical stage. Liaoning Chengda Biotechnology Co.,Ltd. was founded in 2002 and is headquartered in Shenyang, China. Liaoning Chengda Biotechnology Co.,Ltd. is a subsidiary of Liaoning Cheng Da Co., Ltd.
Side-by-side comparison against top Healthcare peers.